Despite these challenges, the U.S. organ transplant system still saves over 48,000 lives a year. And policymakers have been ...

March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial ...

But, for OPTN, an impressive average price target ... a price target is one of many pieces of information about a stock that misleads investors far more often than it guides.

OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago. These figures are ...

OPTINOSE ($OPTN) posted quarterly earnings results on Wednesday, March 26th. The company reported earnings of -$0.03 per share, beating estimates of -$0.72 by $0.69 ...

Claim your 7-day free trial now. OptiNose Inc OPTN shares are trading higher Thursday after Paratek Pharmaceuticals announced a deal to acquire the company. What Happened: Late Wednesday ...

MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (OPTN) (“OptiNose”) to Paratek ...

OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago. These figures are ...